RESULTS OF ALENDRONATE TREATMENT IN PATIENTS DIAGNOSED WITH ASEPTIC OSTEONECROSIS OF THE FEMORAL HEAD

被引:2
作者
Kamal, Kamal Constantin [1 ]
Alexandru, Dragos Ovidiu [2 ]
Rogoveanu, Otilia Constantina [3 ]
Kamal, Diana [4 ]
Buteica, Alice Sandra [5 ]
Balseanu, Tudor Adrian [6 ]
Panus, Camelia [7 ]
Maria, Daniela Teodora [8 ]
Traistaru, Magdalena Rodica [3 ]
机构
[1] Univ Med & Pharm Craiova, Family Med Dept, 2-4 Petru Rares St, Craiova 200349, Romania
[2] Univ Med & Pharm Craiova, Dept Med Informat & Biostat, 2-4 Petru Rares St, Craiova 200349, Romania
[3] Univ Med & Pharm Craiova, Phys & Rehabil Med Dept, 2-4 Petru Rares St, Craiova 200349, Romania
[4] Univ Med & Pharm Craiova, Med Clin Elga, Phys & Rehabil Med Dept, 2 Mihai Eminescu Str, Craiova 200131, Romania
[5] Univ Med & Pharm Craiova, Fac Pharm, 2-4 Petru Rares St, Craiova 200349, Romania
[6] Univ Med & Pharm Craiova, Dept Physiol, 2-4 Petru Rares St, Craiova 200349, Romania
[7] Univ Med & Pharm Craiova, Emergency Clin Cty Hosp Craiova, Dept Diabet Nutr & Metab Dis, 1 Tabaci St, Craiova 200642, Romania
[8] Univ Med & Pharm Craiova, Nephrol Dept, 2-4 Petru Rares St, Craiova 200349, Romania
关键词
aseptic osteonecrosis; femoral head; alendronate; AVASCULAR NECROSIS; NONTRAUMATIC OSTEONECROSIS; BISPHOSPHONATE; COLLAPSE;
D O I
10.31925/farmacia.2019.2.17
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aseptic osteonecrosis of the femoral head is a disabling condition with plurifactorial aetiology, which affects especially young adults. The purpose of the study was to show that alendronate therapy is useful to these patients. We included 34 patients aged 23 to 62 years old, diagnosed in the evolutionary stages II and III, which were divided into two groups. Patients in the first group received treatment with alendronate-70 mg per week plus 5600 IU cholecalciferol for 2 years and conservative treatment. Group II was not treated with alendronate but only conservatively treated. Patients were evaluated from a clinical, imagistic and functional standpoint. In the final evaluation, the imaging aspects improved in patients in the first group. The dual-energy x-ray absorptiometry (DXA) T score, the visual analogue scale (VAS) and the Harris Hip test statistically increased significantly in patients in the first group.
引用
收藏
页码:318 / 322
页数:5
相关论文
共 28 条
[1]   Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study [J].
Agarwala, S ;
Jain, D ;
Joshi, VR ;
Sule, A .
RHEUMATOLOGY, 2005, 44 (03) :352-359
[2]   Alendronate in the treatment of avascular necrosis of the hip [J].
Agarwala, S ;
Sule, A ;
Pai, BU ;
Joshi, VR .
RHEUMATOLOGY, 2002, 41 (03) :346-347
[3]   The use of alendronate in the treatment of avascular necrosis of the femoral head FOLLOW-UP TO EIGHT YEARS [J].
Agarwala, S. ;
Shah, S. ;
Joshi, V. R. .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2009, 91B (08) :1013-1018
[4]   Ten-Year Follow-Up of Avascular Necrosis of Femoral Head Treated With Alendronate for 3 Years [J].
Agarwala, Sanjay ;
Shah, Satyajit B. .
JOURNAL OF ARTHROPLASTY, 2011, 26 (07) :1128-1134
[5]   Osteonecrosis of the Femoral Head [J].
Babis, George C. ;
Sakellariou, Vasileios ;
Parvizi, Javad ;
Soucacos, Panayiotis .
ORTHOPEDICS, 2011, 34 (01) :39-48
[6]   The use of bisphosphonate in the treatment of avascular necrosis: a systematic review [J].
Cardozo, Juliana Bahia ;
Andrade, Debora Motta S. ;
Santiago, Mittermayer B. .
CLINICAL RHEUMATOLOGY, 2008, 27 (06) :685-688
[7]   Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: A two-year multicenter, prospective, randomized, double-blind, placebo-controlled study [J].
Chen, Chung-Hwan ;
Chang, Je-Ken ;
Lai, Kuo-An ;
Hou, Sheng-Mou ;
Chang, Chih-Hao ;
Wang, Gwo-Jaw .
ARTHRITIS AND RHEUMATISM, 2012, 64 (05) :1572-1578
[8]  
[陈树清 CHEN Shuqing], 2011, [中华老年医学杂志, Chinese Journal of Geriatrics], V30, P661
[9]  
Etienne Gracia, 2004, Instr Course Lect, V53, P67
[10]  
Garino JP, 2000, U PEENYLV ORTHOP J, V13, P96